Better Therapeutics plans to launch AspyreRx, a prescription digital therapeutic (PDT) for people with type 2 diabetes, in the fourth quarter of 2023.
AspyreRx, formerly called BT-001, provides cognitive behavioral therapy (CBT) through mobile devices to help people with uncontrolled
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?